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                                                              Abstract 
Molecular interactions between PVT1 transcripts and c-Myc 
It is crucial to understand the interactions of the molecular participants underlying prostate 
cancer.  Prostate cancer (PCa), which is one of the leading causes of death in men worldwide, 
has been shown to be associated with an overexpression of the PVT1 gene. Aggressive prostate 
cancer (PCa) disproportionately affects males of African ancestry (MoAA). The PVT1 gene has 
a strong positive correlation with c-Myc and are both located in close proximity at chromosome 
8q24 in humans. This site is among the top targets of copy number gain and alterations in 
cancer. A previous study done in the Ogunwobi Laboratory demonstrated that PVT1 exon 9 
may be associated with aggressive PCa in MoAA. Additionally, in another unpublished study by 
the Ogunwobi Laboratory, overexpression of PVT1 exons 4A, 4B and 9 is peculiar of PCa in 
MoAA. However, previous works have not investigated the molecular interrelationships between 
PVT1 exons 4A, 4B and 9, regulate and c-Myc located immediately upstream of PVT1 at 
chromosome 8q24. In particular, the PVT1 transcripts that perform the major regulatory tasks in 
this network have not been investigated. This study focused on determining the molecular 
relationships between PVT1 exons 4A, 4B, 9 and c-Myc. 
            To explore this, RWPE-1 cells (non-tumorigenic human prostate epithelial cells) were 
transfected with siRNAs specifically targeting PVT1 exons 4A, or 4B, or 9. The transfected cells 
were then analyzed in turn for the relative expression of PVT1 exons 4A, 4B, 9 and c-Myc by 
quantitative polymerase chain reaction (qPCR). This initial result was validated by the 
transfection of RWPE1 cells with plasmids of PVT1 exons 4A, 4B and 9. Western blots were 
also performed to assess the corresponding effects on c-Myc protein expression.  
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            There is significant regulatory interaction between PVT1 exons 4A, 4B and 9; and c-Myc 
which is strongest between PVT1 exon 9 and c-Myc. Interestingly, the knockdown of PVT1 
exons 4A, 4B and 9 by siRNAs did not suppress c-Myc protein level in RWPE1 cells. 
Nevertheless, PVT1 exon 9 appears to be a major regulatory part of the PVT1 gene.   
            Understanding the roles of the different PVT1 exons, and their regulatory functions in 
relation to c-Myc will likely have implications for prostate cancer and other diseases where 
PVT1 or c-Myc are dysregulated. 
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                                                        Introduction  
Background 
            One in nine men will be diagnosed with prostate cancer during his lifetime [ 1]. Prostate 
cancer is the second leading cause of cancer death in American men, behind lung cancer. About 
one in 41 men will die of prostate cancer. In 2018, there will be about 164,690 new cases of 
prostate cancer and about 29,430 deaths from prostate cancer in the United States based on the 
American Cancer Society’s estimates for prostate cancer for 2018 [1]. The incidence of prostatic 
cancer increases with age. Any man with circulating androgens who lives long enough will 
develop microscopic prostate cancer. The increasing growth in the number and proportion of 
individuals aged 60 years and above means there will be more men diagnosed with prostate 
cancer.  
            The current methods to predict the outcome of prostate cancer are based on PSA levels at 
diagnosis, Gleason score, clinical TNM stage and tumor markers (DNA or RNA). Normograms 
and multifactor classification schemes, based on common factors (age, PSA, Gleason score, 
stage) are used to assess for biochemical relapse (rising PSA and local recurrence) [ 2]. Most of 
those diagnosed will not die of prostate cancer and some may not even need to be treated. 
Current treatment options for localized prostate cancer include watchful waiting, depletion of 
androgens through radical prostatectomy, radiotherapy or pharmacotherapy. While nearly all 
patients respond to androgen deprivation, the response in some patients is short-lived, and the 
disease recurs as castration-resistant prostate cancer (CRPC) [3].  
            Many risk factors including endogenous (age, ethnicity, hormones, family history, 
oxidative stress) and exogenous factors (diet, environmental agents, lifestyle) have been 
attributed to PCa (prostate cancer) [4]. The highest incidence rates for prostate cancer are among 
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African-American men, who have a higher risk of prostate cancer than white American men [4]. 
However, racial disparity may be subsequent to healthcare access dissimilarity, delay in seeking 
medical attention and follow-up, and variations in allelic frequencies of microsatellites at the 
androgen receptor (AR) locus [4].  
            Molecular genetics has also proved to be an invaluable tool in the understanding of PCa. 
Differentiating between aggressive and non-aggressive PCa is required for effective intervention 
in the treatment of PCa. Patients at high risk will be promptly identified and treated 
appropriately. The many prediction tools of PCa survival which are being utilized currently have 
limitations. They are all generally poor prognosticators. Genetic susceptibility studies as well as 
gene expression panels can provide additional tools for the status of PCa progression [5], [6]. For 
example, methylation status of APC, GSTP1, and MDR-1 gene promoters have proven to be 
significantly correlated with clinicopathologic findings in prostate cancer and can be combined 
with the current biomarkers [6].  
            Multiple molecular mechanisms have been implicated in the progression of PCa. They 
include prostate-cancer susceptibility loci, loss of suppressor genes, chromosomal translocation, 
and more importantly, the androgen receptor [7].  Genome-wide analyses have implicated several 
genes and loci associated with risk and progression to PCa. Multiple genome-wide approaches 
can identify genotype germline variants, including both SNPs and CNVs, detect somatic DNA 
copy number changes, and assess DNA methylation status. Genome wide association study 
(GWAS) using blood DNA samples from individuals with clinically detected prostate cancer 
identified 8q24 and 17q as common loci associated with prostate cancer [8]. 
            Many studies have confirmed 8q24 as the most frequently gained chromosomal region in 
prostate tumors [9], [10], and there is great possibility that the associated risk variants and SNPs 
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could predispose to prostate cancer through increased genomic instability [11]. This region is 
home to the MYC proto-oncogene, a well-known protein coding gene. Although MYC is 
frequently found to be amplified across many cancers [12], there appears to be an interplay with 
other 8q24 transcripts. Besides MYC, other transcripts from chromosome 8q24 include 
POU5F1B, PRNCR1 (prostate cancer non‐coding RNA 1), PVT1 (plasmacytoma variant 
translocation; also a non-coding RNA) and a host of PVT1-encoded micro-RNAs ((miR-1204, 
miR-1205, miR-1206, miR-1207-3p, miR-1207-5p, miR-1208) [13]. SNPs studies of 
chromosomes 8q24 have revealed many sites of susceptibility to prostate cancer [8], [11]. 
            Non-coding RNAs (ncRNAs) are RNA transcripts from genes not encoding for a protein 
[14]. Non-coding RNAs can be grouped into two major classes based on the transcript size: (1) 
small ncRNAs less than 200 bp, such as piRNAs (Piwi-associated RNAs), miRNAs 
(microRNAs), and snoRNAs (small nucleolar RNAs), and (2) long ncRNAs (lncRNAs), greater 
than 200 bp. Many studies have demonstrated that the lncRNAs are involved in the regulation of 
many biological processes involving regulation of gene expression, transcription, translation, cell 
cycle control, chromatin modification and cellular differentiation [15], [16], [17], [18], [19], [20], [21], 
[22]. Aberrant expression of lncRNAs have been observed in cancer and may serve as predicting 
tools for patient outcomes [23], [24].  
            Plasmacytoma variant translocation 1 (PVT1), a long non-coding RNA encoded by the 
human PVT1 gene, is in the well-known cancer-related region, 8q24. Chromosome 8q24 copy-
number amplification is one of the most frequent occurrences in many malignant conditions, and 
therefore, PVT1 is an oncogene for many cancers. PVT1 frequently acts as an inducer of cell 
proliferation and an inhibitor of apoptosis. Overall, the expression levels of PVT1 appear to be 
higher (up to 100 times) in cancer cells and tissues than in normal human primary cells and 
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tissues [25], [26]. An increased expression of PVT1 was observed when the risk allele of rs378854 
at chromosome 8q24 is present in prostate tissue, thereby increasing the risk for prostate cancer 
[27]. 
 
PVT1 structure and transcripts 
           The human PVT1 gene is a large locus (>30 kb), spanning from 128806779 to 
129113499, 57 kb downstream of the MYC gene. The PVT1 locus encodes alternative 
transcripts but there are no proteins produced [28], [29]. The PVT1 locus contains a variety of 
exons (12 annotated ones) and are termed 1a, 1b, 1c, 2, 3a, 3b, 4a, 4b, 5, 6, 7, 8, 9 and 10 [30], 
[Figure 1]. Some of the exons are more commonly used than the others. Lots of questions still 
need to be answered regarding the functions of PVT1, though strong suggestions point to its role 
as a regulatory RNA [31]. MicroRNAs have garnered much interest in the past few years 
especially in relation to cancer biogenesis and progression. MicroRNAs (miRNAs) are 19-24 
nucleotide non-coding RNA molecules that regulate the expression of target mRNAs both at the 
transcriptional and translational level [32], [33]. PVT1 encodes six miRNAs, that is miR-1204, 
miR-1205, miR-1206, miR-1207-3p, miR-1207-5p, and miR-1208. PVT1 and miR-1204 have a 
strong correlation of expression as they share promoters and are probably under the same 
regulatory circuit [34], [35]. The other miRNAs have shown possible correlation with different 
cancers but appears to be distinctively regulated [34], [27]. 
PVT1 transcripts and prostate cancer 
            Although many studies have been carried out on the role of PVT1 in cancer, nonetheless, 
the specific roles of PVT1 transcripts in prostate cancer have been examined by very few groups. 
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The Ogunwobi Laboratory reported that PVT1 exon 9 is significantly overexpressed in PCa cell 
lines derived from men of African Ancestry (MoAA) [36]. This observation was made from 
comparing the relative expression of PVT1 exons in different cell lines derived from men of 
different ethnic and racial backgrounds. This novel discovery, if explored, can lead to more 
insights into the molecular mechanisms of the deadly aggressive PCa.  
            Furthermore, the Ogunwobi Laboratory also described correlation between miR-1207-3p 
expression and clinicopathological features of PCa [37]. Increased expression of miR-1207-3p 
was found in PCa tissue samples of patients who succumbed to PCa specific death. 
Paradoxically, the expression of miR-1207-3p in PCa tissues of MoAA (men of African 
Ancestry) was significantly decreased and might explain the genetic differences underlying 
racial disparity in PCa.  Although these studies have opened the possibilities of new diagnostic 
biomarkers in PCa, further clarification are needed to explore how these transcripts are regulated 
and if they regulate each other.  
 
MYC and prostate cancer 
            MYC is one of the well-known oncogenes. The MYC gene encodes for a basic-helix-
loop-helix leucine zipper (bHLH-Zip) transcription factor that can act as an activator and 
repressor. The MYC proto-oncogene family, comprising c-MYC (8q24), n-MYC (2p24) and l-
MYC (1p34), has been shown to be involved in many cellular processes including cell growth 
and proliferation, cell cycle, differentiation, cell adhesion and migration, angiogenesis and 
metabolism [38], [39], [40].  The c-MYC proto-oncogene encodes a transcription factor, c-MYC, 
the cellular homologue to the viral oncogene (v-MYC) of the avian myelocytomatosis retrovirus 
[38]. c-MYC, located at chromosome 8q24, is normally tightly controlled by external signals 
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including growth factors, mitogens and β-catenin, which promote cell proliferation and factors 
such as TGF-β, which inhibit. c-MYC activates a variety of known target genes as part of a 
heterodimeric complex with its partner protein, MAX. MYC–MAX heterodimers bind specific 
DNA sequences, such as the E-box sequence CACGTG found in promoter of the target genes 
[41]. MYC-MAX heterodimers can then regulate transcription of target genes. 
            While many target genes are upregulated by MYC, some genes, particularly those 
participating in cell cycle arrest are downregulated by MYC. c-Myc overexpression is mainly 
due to gene amplification, and it is associated with aggressive PCa and poor clinical prognosis 
[42], [43], [44], [45]. Nevertheless, finding consistent correlation between risk alleles and c-Myc 
expression has proved to be a daunting task in PCa. Studies have revealed conflicting results. For 
example, a study reported upregulated c-Myc expression in association with a risk allele [46], 
while another failed to observe such correlation [47].  
            A more promising and convincing feature is the association of epigenetic markers with 
risk alleles in a tissue specific manner [48], [49]. These studies have demonstrated that regulatory 
elements such as the enhancers in risk loci have cell type specific histone modifications which 
correlate with cell type specific gene expression, and these appear to be tissue specific regulators 
of c-MYC [50], [51], [52]. Sotelo et al, demonstrated that the same mechanism occurs in prostate 
cancer where an enhancer element interacts with the MYC promoter via transcription factor Tcf-
4 binding and operates in a tissue specific manner to regulate MYC expression [53]. But some 
studies have reported conflicting results as well, for instance a risk allele enhancer had 
significant binding activity to both MYC and the nearby PVT1 promoters in a study of the 8q24 
PCa risk locus and MYC expression [54]. 
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            Activation of the proto-oncogene c-Myc is one of the earliest somatic molecular 
alterations that occur at the transition in benign prostatic epithelial cells to PIN (prostatic 
intraepithelial neoplasia) and adenocarcinoma. Other epigenetic changes at this stage may 
include GSTP1 promoter hypermethylation, and telomere shortening [55], [ 56]. In prostate 
cancer, studies have shown highly consistent upregulation of c-Myc at the mRNA level in most 
patient samples [57], [58], [59]. Similarly, c-Myc protein was frequently overexpressed in PIN, 
incrementally from normal to low-grade PIN to high-grade PIN [55]. Additionally, 
overexpression of c-Myc in mouse models suggests that c-Myc is sufficient to transform normal 
prostatic cells into PIN [60], [61], however, some studies demonstrated that such transformation 
occur only when c-Myc acted in conjunction with other genes [62], [63]. 
            Direct inhibition of the overexpression of c-Myc in cancers has been difficult to achieve 
because of the numerous factors affecting its high turnover rate in cells. While there are many 
potential pathways to targeting c-Myc in cancers, it has not proved to be effective in clinical 
treatment. One of the emerging paths of evaluating c-Myc is by its regulation of the non- coding 
RNAs, particularly the lncRNAs (long non-coding RNAs) [64], [65], [66]. c-Myc has been shown 
to have pronounced effect on lncRNA transcription in the MYC-inducible cell line P493-6 [67], 
[68]. Several lncRNAs have been implicated in the regulation of c-Myc in prostate cancer.  PVT1 
can also be transcriptionally activated by c-Myc [69]. Other examples of lncRNAs regulated by c-
Myc in PCa cancer cells include PCAT1 [70], and PCGEM1 [71]. lncRNAs are certainly not the 
only group of non-coding RNAs regulating c-Myc. In an unpublished study by the Ogunwobi 
Laboratory, miR-1207-3p which is encoded at the PVT1 gene locus suppressed c-Myc 
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expression in aggressive CRPC cell lines suggesting an example of the regulation of c-Myc by a 
microRNA in PCa [72]. As better understanding of the roles of non-coding RNAs in cancer 
regulation is being unraveled, their potentials as biomarkers will likely become better 
appreciated.   
 
PVT1 and c-Myc interactions in prostate cancer 
            Molecular interactions between PVT1 and c-Myc are inevitable given their proximity on 
the 8q24 chromosomal locus. Many studies have long established the co-amplification of c-Myc 
and PVT1 in many cancers [73], [74], [75]. PVT1 has been shown to be an activator of c-Myc 
transcription, and likewise, c-Myc has also been implicated as a PVT1 activator in cancer cells 
[28], [74], [76]. The human PVT-1 gene contains two non-canonical MYC-binding sites (E-box 
CACGCG) in the promoter region proximal to the transcriptional start site [77]. In a study by 
Carramusa and colleagues, it was indicated that one of the two E-boxes is important for PVT1 
promoter transcriptional regulation by c-Myc proteins [77]. ChIP analysis of the same region in 
neuroblastoma cells revealed a novel network between PVT1 and N-Myc. 
            The possibility of common functional pathways has been described, yet, there is also 
evidence for independent contribution of PVT1 and MYC to tumorigenesis. By utilizing 
transgenic mice models, it was demonstrated that a combination of PVT1 and MYC is essential 
to the formation of tumors [78]. In this instance, PVT1 might be regulating and stabilizing the 
MYC protein by preventing MYC from proteolytic degradation. Alternatively, PVT1 
contribution to tumorigenesis may be independent of MYC [25]. This suggests different 
mechanisms of PVT1 and MYC cooperation in different cancers. 
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            In prostate cancer cell lines, PVT1 knockdown significantly downregulated the 
expression of c-Myc as compared to the control [79]. A similar regulation of c-Myc protein by 
PVT1 was observed upon PVT1 knockdown by RNA interference in acute promyelocytic 
leukemia [80]. PVT1 knockdown had no effect on c-Myc RNA but led to the suppression of the 
MYC protein level in NB4 cells. Using genome-wide association studies (GWAS), MYC and 
PVT1 at 8q24.21 were identified as physically interacting genes at risk SNP loci in most prostate 
cancer cell lines [81]. The interaction of the chromatin at this risk loci suggests that several 
regulatory elements are aggregated in multiple fragments to enable gene expression. This might 
provide some explanation for the PVT1 and MYC interaction in PCa. 
            A very recent study has brought better illumination to the PVT1 and MYC regulatory 
network. It showed that the PVT1 promoter, as a DNA element, constrains MYC transcription, 
whereas the PVT1 RNA product sustains the MYC protein level [82]. The mechanisms of PVT1 
and MYC interactions are still not very clear but as more research is being done, better 
understanding of the processes involved are being gained. 
 
Project Rationale 
            A previous study done in the Ogunwobi Laboratory [36] has shown that PVT1 exon 9 
expression in aggressive PCa cell lines derived from MoAA (men of African Ancestry) was 
significantly higher than in less aggressive PCa cell lines and PCa cell lines derived from men of 
other ancestry. This suggests that PVT1 exon 9 may be associated with aggressive PCa, which 
disproportionately affects MoAA. Furthermore, in another study from the Ogunwobi Laboratory, 
PVT1 exons 4A, 4B and 9 were found to be overexpressed in PCa tissues from MoAA [83]. 
Based on these previous studies, this project seeks to address the molecular interactions between 
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the transcripts from PVT1 exons 4A, 4B, and 9, and if there is any positive correlation with c-
Myc in non-tumorigenic prostate epithelial cells. A better understanding of the interplay between 
PVT1 transcripts and c-Myc in non-tumorigenic prostate epithelial cells will provide valuable 
insights to the underlying mechanisms of dysregulation in PCa.      
            Based on the above, we hypothesize that one or more of the transcripts from PVT1 exons 
4A, 4B, or 9 may be positively correlated with the other in prostate epithelial cells, and that one 
or more of these transcripts may have a major regulatory role in PVT1 and c-Myc function in 
prostate epithelial cells. 
Experimental Workflow 
            RWPE1 cells derived from non-tumorigenic prostate epithelial cells were transfected 
separately with siRNAs specifically targeting PVT1 exons 4A, 4B, and 9. For each PVT1 exon 
knockdown, the expression of the silenced exon was verified by RNA extraction and qPCR using 
custom-designed primers All mRNA expression for PVT1 exons and for c-Myc were determined 
using RNA extraction, cDNA synthesis, and qPCR. 
            Subsequently, the roles of PVT1 exons 4A, 4B and 9 were confirmed by transfecting 
RWPE1 cells with plasmid vectors expressing PVT1 exons 4A, or 4B, or 9, separately. The 
mRNA expression of the PVT1 exons and c-Myc was then determined by RNA extraction, 
cDNA synthesis, and qPCR, as before.  
            Western blotting was also carried out to examine the expression of c-Myc protein in both 
RWPE-1 cells transfected with above mentioned siRNAs. All the experiments described 
included appropriate negative controls at each step. 
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            Next, the individual expression of PVT1 exons 4A, 4B and 9 in (non-transfected) 
RWPE1 cells was examined. The PCR products were then run on a 1.5% agarose gel and sent 
out for sequencing to verify the identity of the exons. The PCR sequence of each exon was then 
run through Blast (Basic Local Alignment Search Tool) to check for sequence similarity 
(homology) among the exons. 
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Materials and Methods 
 
Cell Line 
RWPE1 cells were used for this study. RWPE1 cells are epithelial cells derived from the 
peripheral zone of a histologically normal prostate from a 54-year-old Caucasian male (CM). 
The cells were transfected with a single copy of the human papilloma virus 18 (HPV-18) to 
establish the cell line. RWPE1 is non-tumorigenic. The cells were purchased from the American 
Type Culture Collection (ATCC, Manassas, VA, USA). 
 
Cell Culture and Cell Culture Reagents 
RWPE1 cells were maintained in Keratinocyte-Serum Free Medium (Life Technologies, Grand 
Island, NY, USA), supplemented with 0.05 mg/mL bovine pituitary extract and 5 ng/mL human 
Epidermal Growth Factor and, 1% Penicillin/Streptomycin. 
 
PVT1 Exons 4A, 4B and 9 knockdown using small interfering RNA (siRNA) 
RWPE1 cells were grown in a monolayer in 6-well plates until 70%–80% confluent. SiRNA 
(Small interfering RNA) transfection was performed. Cells were transfected with PVT1 exon 9 
siRNA, PVT1 exon 4A siRNA, PVT1 exon 4B siRNA with 30 pmol final concentration per well 
using lipofectamine RNAiMax (Invitrogen Inc., Carlsbad, CA) in Opti-MEM (1X) reduced 
serum media (Gibco). A non-specific (scramble) control siRNA was also transfected at the same 
concentration as the negative control. Cells were incubated at 37° C for 72 hours. The cells were 
then harvested and lysed. 
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Over-expression of PVT1 Exons 4A, 4B and 9 
PVT1 exons 4A, 4B and 9 were subcloned into vector pcDNA3.1(+). RWPE1 cells were 
transfected with the positive vector or with the empty vector as control. Transfection was 
conducted utilizing Lipofectamine 3000 (Invitrogen) according to the manufacturer’s 
instructions. 
 
RNA Extraction and qPCR 
Total RNA was extracted from transfected cells using RNeasy Mini Kit (Qiagen, Germany, cat# 
74104). After quantification with Nanodrop1000 spectrophotometer (NanoDrop, Madison, WI, 
USA), 1 μg of RNA was reverse-transcribed into cDNA using QuantiTect Reverse Transcription 
kit (Qiagen, Germany, cat# 205311). Amplification reactions were performed in 25 μL reaction 
volume using SYBR Green PCR master Mix (Life Technologies, Grand Island, NY, USA cat# 
4309155), cDNA template and 0.4 _M final concentration for primers. The thermal cycle profile 
employed was as follows: 50 _C for 2 min, 10 min initial denaturation at 95 °C, and 40 cycles of 
15 s denaturation at 94 °C, 1 min annealing at 65 °C. A dissociation curve was also added at the 
end of the cycle. The amplifications were carried out on the 7500 Real Time PCR machine 
(Applied Biosystems instruments, Grand Island, NY, USA). Messenger RNA (mRNA) 
expression was assessed in quadruplicates in at least 3 independent experiments and normalized 
to GAPDH mRNA expression. Relative expression levels were calculated by the Ct method (DD 
Ct). 
 
Primer Design and Sequences 
All primer Design and Sequences are as previously described [36].  
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Agarose gel electrophoresis of PCR products of amplified PVT1 exons 4A, 4B and 9.  
Agarose gel electrophoresis was performed in 1.5% agarose gels (Amresco) containing 15 μg of 
ethidium bromide per ml. The gels were electrophoresed on Shelton Scientific IBI® Horizontal 
Gel Systems: High Resolution & High Throughput Design, 20 x 25 cm, for 40 minutes at a 
constant voltage of 100 V and were analyzed by photographing them as they were exposed to 
UV light (UVP Inc., Upland, Calif.). Gels were photographed and digitized with the 
FOTO/Analyst Archiver system (Fotodyne, Inc., Hartland, Wis.).  
 
Direct Sequencing of PCR products of amplified PVT1 exon 9, exon 4A and exon 4B 
PCR products of amplified exons were purified by QIAquick PCR Purification Kit (Qiagen, 
Valencia, CA) and sent for sequencing at Eton Bioscience, Inc.  
 
Western blot analysis  
RWPE1 cells were transfected with specific siRNAs for PVT1 exons 4A, or 4B or 9 separately 
or siRNA controls and lysed using RIPA buffer (Pierce) containing a protease inhibitor cocktail 
(Sigma-Aldrich). Equivalent amounts of total protein were separated on SDS/PAGE gels and 
blotted to a nitrocellulose membrane. The membranes were blocked with 5% BSA and then 
incubated with primary antibodies probing for c-Myc (Proteintech Group Inc) and α-tubulin 
(Rockland antibodies and assays) separately at 4°C overnight. Membranes were later incubated 
with the appropriate secondary antibodies after washes with TBST.  The western blots were 
analyzed and quantified with Odyssey imager, Image Studio version 5. 
 
Bioinformatics 
BLAST (Basic Local Alignment Search Tool) at NCBI (http:// www.ncbi.nlm.nih.gov) was done 
to confirm the identity of the amplified PVT1 exons and examine for sequence homology.  
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Statistical analysis 
Data are presented as mean ± standard error of the mean (S.E.M) of at least three independent 
experiments. Statistical significance of differences was assessed using two-tailed Student’s t test. 
p values less than 0.05 were deemed significant. 
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Results 
 
A. Silencing PVT1 exon 9 decreases the expression of exon 4A, exon 4B and c-Myc 
To examine the molecular relationship between PVT1 exons 4A, 4B, 9, and c-Myc in prostate 
cells, the relative expression of transcripts was assessed after knocking down the PVT1 exons. 
Each PVT1 exon was knocked down by siRNA specifically targeting it. Using qPCR, the 
expression of each exon knocked down was confirmed to be lower than that in cells transfected 
with the negative control. Figure 2 showed a significant decrease in the expression level of the 
exons after siRNA transfection compared with the matching negative control. As shown in figure 
2A, the relative expression of PVT1 exon 4B and PVT1 exon 9, was not statistically significant 
(p value=0.22 and p value=0.10 respectively) after knocking down PVT1 exon 4A. However, 
there is a 30% decrease in the relative expression of c-Myc observed with PVT1 exon 4A knock 
down (fig. 2A) which is statistically significant at p value=0.04. PVT1 exon 4B knock down 
produced a decrease in the expression level of the other exons. But this decrease in the relative 
level of expression is not statistically significant for PVT1 exon 9 (fig. 2B) and PVT1 exon 4A 
(fig. 2B) (p value=0.07, and p value=0.17 respectively). C-Myc level of expression was found to 
be slightly higher than the control (fig. 2B; approximately 1% increase). Taken together, PVT1 
exon 4B seems to modulate the expression of PVT1 exon 4A, PVT1 exon 9; and c-Myc through 
some as yet unknown mechanisms. 
PVT1 exon 9 silencing (fig. 2C) revealed a consistent pattern of more than 50% decrease 
in the relative expression of PVT1 exon 4A (p value=0.005) and PVT1 exon 4B (p value=0.001). 
Effect of PVT1 exon 9 silencing on the relative expression of c-Myc is also significant (p 
value=0.05) (fig. 2C). Consequently, PVT1 exon 9 appears to regulate PVT1 exons 4A and 4B 
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and c-Myc. This finding suggests that PVT1 exon 9 is a major regulatory component of the 
PVT1 gene. 
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Figure 2. Silencing PVT1 exon 9 decreases the expression of exon 4A, exon 4B, and c-Myc. Transfection of siRNA Control or siRNA 
targeting PVT1 exon 4A, 4B and 9 in RWPE1 cells. Each exon knockdown was initially assessed and verified by qPCR.  (A) The effect of PVT1 
exon 4A knockdown on mRNA levels of exon 9, 4B and c-Myc. Data shows that there is no consistent pattern in relative expression of these 
exons compared with the control. (B) The effect of PVT1 exon 4B knockdown on mRNA levels of exon 9, 4A and c-Myc. The relative 
expression level of these exons was not statistically significant. (C) The effect of PVT1 exon 9 knockdown on mRNA levels of exon 4A, 4B and 
c-Myc was generally consistent and significant. (Three independent qPCR experiments were performed, and every experiment was set up in 
quadruplicates. All values are mean ± SD. p < 0.05 is statistically significant).  
 
 
B. Overexpression of PVT1 exon 4A, exon 4B, and 9 validates the molecular relationship 
between these exons and c-Myc. 
  
To confirm the regulatory roles of the PVT1 exons as suggested by siRNA studies, PVT1 exons 
4A, 4B, and 9 were subcloned into plasmid vectors and transfected separately into RWPE-1 
cells. The relative expression of each exon and c-Myc was then verified by qPCR. PVT1 exons 
4A and 4B overexpression induced a significant increase in c-Myc expression at p 
value=0.001(fig. 3A) and p value=0.04 (fig. 3B) respectively. This suggests a positive 
correlation between these exons and c-Myc. Overall, PVT1 exons 4A, 4B, and 9 all 
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significantly induced c-Myc expression. However, PVT1 exons 4A and 4B might contribute 
more to the regulation of c-Myc.   
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Figure 3. Overexpression of PVT1 exon 4A, exon 4B, and exon 9 validates the molecular relationship between these exons and c-Myc. 
Transfection of control (empty vector) or Plasmid PVT1 exon 4A, 4B and 9 in RWPE-1 cells. The expression of each transfected exon was 
initially assessed and verified by qPCR. (A) The effect of transfected plasmid PVT1 exon 4A resulted in more than 20% increase in the mRNA 
expression level of exon 4B, 9 and c-Myc. (B) The effect of transfected plasmid PVT1 exon 4B resulted in an average of 15% increase in the 
mRNA expression level of exon 4B, and exon 9 compared with the control. The effect on c-Myc is about 50% increase, is statistically significant 
and appears to have a positive correlation. (C) Transfection of plasmid PVT1 exon 9 resulted in an increase of about 15% in the mRNA 
expression level of exon 4A, exon 4B, and c-Myc compared with the control. (Three independent qPCR experiments were performed, and every 
experiment was set up in quadruplicates. All values are mean ± SD. p < 0.05 is statistically significant).  
 
C. PVT1 exon 9 is abundantly expressed in RWPE1 cells and is a regulatory portion of 
the PVT1 gene. 
 Further characterization of PVT1 exons 4A, 4B and 9 was carried out based on the observations 
above. Analysis of the relative expression of PVT1 exons 4A, 4B and 9 by qPCR showed PVT1 
exon 9 as the most abundantly expressed of the three exons in the non-tumorigenic RWPE1 
prostate epithelial cell line. PVT1 exon 9 is about 50% more in expression level compared with 
PVT1 exon 4A (fig. 4A), while it is about 25% more compared to PVT1 exon 4B (fig. 4A). 
Additionally, the PCR products of these exons were subjected to 1.5% agarose gel 
electrophoresis which revealed that exon 9 is about 250 bp in size (fig. 4B), while exon 4A and 
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exon 4B are about 230 bp and 120 bp respectively (fig. 4B). Next, the PCR products were 
sequenced, and the exon DNA sequences were analyzed for homology and identity with BLAST 
(Basic Local Alignment Search Tool). PVT1 exon 9 was identified by BLAST as 
[>NR_003367.3 Homo sapiens Pvt1 oncogene (non-protein coding) (PVT1), long non-coding 
RNA] and identity of 83%. Exon 4A did not reveal any significant homology. However, it 
produced significant alignment when compared with PVT1 exon 4A in the database. 
Exon 4B sequence revealed an identity of 83% and was reported as >NR_003367.3 Homo 
sapiens Pvt1 oncogene (non-protein coding) (PVT1), long non-coding RNA 
[GCAGCAAGCACCTGTTACCTGTCCACCCCCACCCCTTCCCCCAAACTGCCTTTGAAA
AATCCCT] >NR_003367.3 Homo sapiens Pvt1 oncogene (non-protein coding) (PVT1), long 
non-coding RNA [CCTGTTACCTGTCCACCCCCACCCCTTCCCCCAAACTG] 
>NR_003367.3 Homo sapiens Pvt1 oncogene (non-protein coding) (PVT1), long non-coding 
RNA[CCTTATGGCTCCACCCAGAAGCAATTCAGCCCAACAGGAGGACAGCTTCA] 
Comparisons by BLAST between exon 4A, 4B and 9 revealed no significant similarity. This 
suggests very distinct identities for these PVT1 exons.  
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Figure 4. PVT1 exon 9 is abundantly expressed in RWPE-1 and is a regulatory portion of the PVT1 gene. (A) Relative expression of PVT1 
expression exon 9, exon 4A and exon 4B. Exon 9 has the highest level of expression among these exons in RWPE1 cells and is a regulatory 
portion of the PVT1 gene. (B) PCR products of the exons on 1.5% agarose gel revealed the individual bp lengths. (Three independent qPCR 
experiments were performed, and every experiment was set up in quadruplicates. All values are mean ± SD. p < 0.05 is statistically significant). 
 
D   c-Myc is regulated by PVT1 exon 9 transcriptionally. 
 To further evaluate the association between PVT1 exons 4A, 4B and 9, and c-Myc , RWPE-1 
cells were transfected with siRNAs specifically targeting the exons, in addition to a control 
siRNAs. c-Myc protein level was then analyzed by Western blot. This was also performed to 
verify if PVT1 exon 9 regulates c-Myc at the post-transcriptional level. Western blot analyses 
done with repeated experiments showed some correlation between PVT1 exon 9 and c-Myc 
protein (fig. 5). However, this correlation is not statistically significant. c-Myc appears to be 
regulated by PVT1 exons, notably exon 9 at the transcriptional level in RWPE1 cells. 
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Figure 5. c-Myc is regulated by PVT1 exon 9 transcriptionally. Western blot analysis of c-Myc protein in RWPE1 cells. RWPE1 cells were 
transfected with siRNA PVT1 exon 9, exon 4A and 4B, in addition to siRNA Control. No significant correlation between the exons and c-Myc 
protein was found. Western blot experiments were performed three separate times. 
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Discussion 
            This study will bring better understanding of the roles played by the different PVT1 
exons in prostate cancer. PVT1 is one of the well-known lncRNA genes associated with cancer. 
Many studies support the hypothesis that c-Myc and PVT1 form part of an interactive network in 
many cancers, whereby PVT1 regulates c-Myc post-translationally [78], [80]. But the question of 
which PVT1 exon plays a regulatory role in this participation with c-Myc still remains. 
            This study was carried out to elucidate the associations between the PVT1 exons 4A, 4B, 
9, and c-Myc in RWPE-1 cells. RWPE-1 cells are derived from normal human prostate epithelial 
cells. The basis for using RWPE-1 cells is to observe the molecular relationships between these 
exons and c-Myc in the normal prostate. It is believed that knowledge of these processes will 
facilitate our understanding of PVT1 dysregulation in prostate cancer.  In this study, silencing 
PVT1 exons 4A, 4B and 9 decreased the level of expression of each exon and c-Myc at the 
transcriptional level. PVT1 exon 9 was found to have a more significant correlation compared 
with PVT1 exon 4A and PVT1 exon 4B. The strongest evidence for the role of PVT1 exon 9 is 
the statistically significant decrease in the level of expression of PVT1 exon 4A, PVT1 exon 4B 
and c-Myc when it was silenced. PVT1 exon 9 was also found to have the highest level of 
expression among these exons in RWPE-1 cells. This suggests that PVT1 exon 9 is a major 
regulatory part of the PVT1 gene.  
There was no significant regulatory effect found between these exons and c-Myc protein. 
This may be attributed to many factors including the fact that RWPE1 cells are not transformed 
(not cancerous), c-Myc protein might be low in these cells and may even be degraded rapidly. 
Silencing PVT1 exon 9 decreases the level of c-Myc protein slightly and appears to regulate c-
Myc at the post-transcriptional level, as well as at the transcriptional level. This will need 
additional studies to confirm.  
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Identifying these molecular relationships will assist in furthering our understanding of 
PVT1 and c-Myc, and their roles in prostate cancer and other diseases where they are 
dysregulated. 
 
Future Directions 
Additional studies will need to be carried out for more detailed explanation for the roles of these 
PVT1 exons, particularly for exon 9. Utilizing CRISPRi to silence the exons will yield better 
results in these experiments. Identifying the sites of PVT1 exons–c-Myc protein interactions may 
determine the mechanisms of regulation involved. Determining the half-life studies of c-Myc 
protein in RWPE-1 cells can highlight how these exons regulate c-Myc protein. In vivo studies 
involving PVT1 exons 4A, 4B, and 9 can be very helpful in translating these interactions to 
clinical strategies. Furthermore, the role of the PVT1 exons in the stability of c-Myc protein, if 
examined, will expand the understanding of PVT1 and c-Myc interactions.   
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